The Incredible Dividend Map... Where Stocks Yield 26% a Year!

What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.

PSTX Insider Trading (Poseida Therapeutics)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 29.20%

Insider Buying (Last 12 Months): $9,260,612.00

Insider Selling (Last 12 Months): $1,225,702.98

Poseida Therapeutics Insider Trading History Chart

Poseida Therapeutics Share Price & Price History

^$4.34

▲ +0.04 (0.93%)

As of 08/16/2022 01:00 AM ET

Days: 30 | 90 | 365

The Safest Option in Trades!

From Tradewins | Ad

If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!

Click here now!

Poseida Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/8/2022	Eric Ostertag	Chairman	Buy	142,857	$3.50	$499,999.50	838,824
8/8/2022	Life Sciences Holdings L Malin	Major Shareholder	Buy	2,150,000	$3.50	$7,525,000.00	11,835,673
8/3/2022	Eric Ostertag	Chairman	Sell	160,696	$3.69	$592,968.24	695,967
3/16/2022	Kerry D. Ingalls	COO	Buy	3,000	$3.98	$11,940.00
12/6/2021	Life Sciences Holdings L Malin	Director	Buy	1,828	$6.90	$12,613.20
12/1/2021	Life Sciences Holdings L Malin	Director	Buy	18,365	$6.85	$125,800.25
11/29/2021	Life Sciences Holdings L Malin	Director	Buy	11,057	$6.89	$76,182.73
11/26/2021	Life Sciences Holdings L Malin	Director	Buy	27,251	$6.81	$185,579.31
11/23/2021	Life Sciences Holdings L Malin	Director	Buy	14,625	$6.77	$99,011.25
11/18/2021	Life Sciences Holdings L Malin	Director	Buy	71,312	$7.18	$512,020.16
11/17/2021	Kerry D. Ingalls	COO	Buy	2,000	$7.00	$14,000.00
11/16/2021	Life Sciences Holdings L Malin	Director	Buy	27,680	$7.17	$198,465.60
11/8/2021	Eric Ostertag	CEO	Sell	18,924	$7.09	$134,171.16
10/1/2021	Eric Ostertag	CEO	Sell	20,029	$7.02	$140,603.58
9/20/2021	Eric Ostertag	CEO	Sell	20,000	$8.00	$160,000.00
9/14/2021	Eric Ostertag	CEO	Sell	20,000	$8.14	$162,800.00
8/20/2021	Matthew A. Spear	Insider	Sell	4,000	$8.79	$35,160.00	45,485
7/1/2021	Eric Ostertag	CEO	Sell	20,563	$9.77	$200,900.51
6/11/2021	Matthew A. Spear	Insider	Sell	4,000	$9.44	$37,760.00	20,485
6/1/2021	Eric Ostertag	CEO	Sell	41,194	$8.61	$354,680.34	542,985
5/3/2021	Eric Ostertag	CEO	Sell	18,326	$9.01	$165,117.26	542,985
4/21/2021	Matthew A. Spear	Insider	Sell	4,000	$8.44	$33,760.00	15,485
4/5/2021	Eric Ostertag	CEO	Sell	57,819	$9.66	$558,531.54	542,985
4/1/2021	Eric Ostertag	CEO	Sell	57,181	$9.55	$546,078.55	542,985
2/16/2021	Eric Ostertag	CEO	Sell	133,149	$10.00	$1,331,490.00	431,590
2/10/2021	Eric Ostertag	CEO	Sell	12,389	$10.00	$123,890.00	431,590
1/21/2021	Eric Ostertag	CEO	Sell	4,462	$10.00	$44,620.00	364,056
7/14/2020	Sean Murphy	Director	Buy	10,000	$16.00	$160,000.00	10,000

A One Stop Shop for Everything Futures Trading

From RJO Futures | Ad

Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!

Download your FREE Technical Analysis Trading Guide Today.

SEC Filings (Institutional Ownership Changes) for Poseida Therapeutics (NASDAQ:PSTX)

41.89% of Poseida Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Poseida Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/16/2022	Corton Capital Inc.	14,978	$39K	0.0%	-74.2%	0.018%
8/16/2022	Delphia USA Inc.	15,799	$41K	0.0%	-61.2%	0.019%
8/15/2022	State Street Corp	92,967	$0.24M	0.0%	-82.5%	0.112%
8/15/2022	Citadel Advisors LLC	72,574	$0.19M	0.0%	+156.1%	0.088%
8/15/2022	Laurion Capital Management LP	545,700	$1.41M	0.0%	N/A	0.660%
8/15/2022	Millennium Management LLC	1,012,515	$2.61M	0.0%	+21.3%	1.224%
8/13/2022	Renaissance Technologies LLC	380,100	$0.98M	0.0%	+103.3%	0.606%
8/12/2022	Northern Trust Corp	50,246	$0.13M	0.0%	-79.0%	0.080%
8/12/2022	FMR LLC	9,405,708	$24.27M	0.0%	+0.3%	11.369%
8/11/2022	JPMorgan Chase & Co.	234,184	$0.60M	0.0%	-26.5%	0.373%
8/10/2022	Forefront Analytics LLC	23,370	$61K	0.0%	-12.7%	0.037%
7/25/2022	Silverarc Capital Management LLC	380,606	$0.98M	0.3%	+58.8%	0.607%
5/23/2022	Cantor Fitzgerald L. P.	30,205	$0.14M	0.0%	+19.8%	0.048%
5/17/2022	Delphia USA Inc.	40,733	$0.18M	0.1%	N/A	0.065%
5/16/2022	Goldman Sachs Group Inc.	56,477	$0.25M	0.0%	-27.5%	0.090%
5/16/2022	State Street Corp	531,573	$2.38M	0.0%	-2.3%	0.850%
5/16/2022	Prelude Capital Management LLC	11,250	$50K	0.0%	N/A	0.018%
5/13/2022	Silverarc Capital Management LLC	239,696	$1.07M	0.4%	+2.0%	0.383%
5/13/2022	Renaissance Technologies LLC	187,000	$0.84M	0.0%	+456.5%	0.299%
5/13/2022	Northern Trust Corp	239,289	$1.07M	0.0%	-5.0%	0.383%
5/13/2022	Charles Schwab Investment Management Inc.	220,090	$0.99M	0.0%	+3.9%	0.352%
5/13/2022	Vanguard Group Inc.	1,446,264	$6.48M	0.0%	-0.4%	2.312%
5/13/2022	Dimensional Fund Advisors LP	144,567	$0.65M	0.0%	+48.5%	0.231%
5/12/2022	BlackRock Inc.	2,468,954	$11.06M	0.0%	-3.3%	3.947%
5/12/2022	Martingale Asset Management L P	16,116	$73K	0.0%	-32.0%	0.026%
5/11/2022	JPMorgan Chase & Co.	318,676	$1.43M	0.0%	+7.0%	0.509%
5/9/2022	Forefront Analytics LLC	26,770	$0.12M	0.0%	+152.1%	0.043%
5/5/2022	MCF Advisors LLC	57,469	$0.26M	0.0%	N/A	0.092%
5/5/2022	Russell Investments Group Ltd.	9,407	$42K	0.0%	-66.6%	0.015%
4/29/2022	Nisa Investment Advisors LLC	13,000	$58K	0.0%	N/A	0.021%
4/19/2022	Regent Investment Management LLC	20,922	$94K	0.0%	-16.3%	0.033%
2/14/2022	Blair William & Co. IL	48,963	$0.33M	0.0%	N/A	0.078%
2/14/2022	GSA Capital Partners LLP	84,701	$0.58M	0.1%	N/A	0.136%
2/8/2022	Northern Trust Corp	251,793	$1.72M	0.0%	-2.0%	0.403%
2/2/2022	New York State Common Retirement Fund	11,972	$82K	0.0%	-42.1%	0.019%
1/21/2022	Russell Investments Group Ltd.	28,178	$0.19M	0.0%	-25.2%	0.045%
1/18/2022	Central Bank & Trust Co.	7,608	$52K	0.0%	+1,579.5%	0.012%
11/17/2021	Altium Capital Management LP	32,238	$0.24M	0.1%	N/A	0.052%
11/16/2021	Schonfeld Strategic Advisors LLC	289,179	$2.11M	0.0%	+13.6%	0.463%
11/16/2021	Millennium Management LLC	909,856	$6.63M	0.0%	-13.0%	1.456%
11/15/2021	Pura Vida Investments LLC	114,343	$0.83M	0.0%	-20.1%	0.183%
11/15/2021	Voya Investment Management LLC	13,813	$0.10M	0.0%	-87.9%	0.022%
11/15/2021	Martingale Asset Management L P	15,615	$0.11M	0.0%	N/A	0.025%
11/12/2021	Trexquant Investment LP	12,442	$91K	0.0%	N/A	0.020%
11/12/2021	MCF Advisors LLC	66,185	$0.48M	0.0%	+80.1%	0.106%
11/10/2021	Goldman Sachs Group Inc.	57,175	$0.42M	0.0%	+65.9%	0.092%
11/9/2021	BlackRock Inc.	2,533,139	$18.47M	0.0%	-0.3%	4.063%
11/8/2021	Russell Investments Group Ltd.	37,662	$0.27M	0.0%	-3.7%	0.060%
11/5/2021	Advisory Services Network LLC	268,290	$1.96M	0.1%	+4.5%	0.430%
11/5/2021	Privium Fund Management UK Ltd	48,470	$0.35M	0.4%	N/A	0.078%
11/2/2021	New York State Common Retirement Fund	20,681	$0.15M	0.0%	+43.1%	0.033%
11/1/2021	SG Americas Securities LLC	21,323	$0.16M	0.0%	N/A	0.034%
9/3/2021	Parametric Portfolio Associates LLC	36,961	$0.37M	0.0%	N/A	0.059%
8/17/2021	Millennium Management LLC	1,046,123	$10.48M	0.0%	-40.7%	1.683%
8/17/2021	Balyasny Asset Management LLC	80,202	$0.80M	0.0%	N/A	0.129%
8/17/2021	Boothbay Fund Management LLC	13,304	$0.13M	0.0%	N/A	0.021%
8/16/2021	California State Teachers Retirement System	39,657	$0.40M	0.0%	-20.6%	0.064%
8/16/2021	Schonfeld Strategic Advisors LLC	254,603	$2.55M	0.0%	-38.8%	0.410%
8/16/2021	Pinz Capital Management LP	11,200	$0.11M	0.0%	N/A	0.018%
8/16/2021	Charles Schwab Investment Management Inc.	128,065	$1.28M	0.0%	-9.5%	0.206%
8/16/2021	State Street Corp	513,992	$5.15M	0.0%	+13.8%	0.827%
8/16/2021	Federated Hermes Inc.	16,656	$0.17M	0.0%	N/A	0.027%
8/16/2021	Goldman Sachs Group Inc.	34,457	$0.35M	0.0%	-12.2%	0.055%
8/13/2021	Northern Trust Corp	245,069	$2.46M	0.0%	+48.1%	0.394%
8/13/2021	Geode Capital Management LLC	376,544	$3.77M	0.0%	-6.5%	0.606%
8/13/2021	Vanguard Group Inc.	1,330,451	$13.33M	0.0%	-7.4%	2.141%
8/13/2021	FMR LLC	9,323,206	$93.42M	0.0%	+0.1%	15.000%
8/13/2021	ProShare Advisors LLC	18,630	$0.19M	0.0%	+6.9%	0.030%
8/12/2021	JPMorgan Chase & Co.	312,694	$3.13M	0.0%	+0.6%	0.503%
8/12/2021	Ergoteles LLC	28,300	$0.28M	0.0%	N/A	0.046%
8/11/2021	Bank of New York Mellon Corp	82,900	$0.83M	0.0%	+31.4%	0.133%
8/11/2021	BlackRock Inc.	2,541,825	$25.47M	0.0%	-10.1%	4.089%
8/11/2021	Deutsche Bank AG	17,075	$0.17M	0.0%	-22.3%	0.027%
8/10/2021	Virtus ETF Advisers LLC	24,287	$0.24M	0.1%	N/A	0.039%
8/10/2021	Citigroup Inc.	5,937	$59K	0.0%	+76.0%	0.010%
8/5/2021	Rhumbline Advisers	30,461	$0.31M	0.0%	+37.5%	0.049%
8/4/2021	Russell Investments Group Ltd.	39,127	$0.39M	0.0%	+157.6%	0.063%
8/2/2021	New York State Common Retirement Fund	14,456	$0.15M	0.0%	-30.2%	0.023%
6/5/2021	Advisory Services Network LLC	256,771	$2.45M	0.1%	N/A	0.413%
5/18/2021	Millennium Management LLC	1,764,505	$16.85M	0.0%	+19.7%	2.839%
5/18/2021	California State Teachers Retirement System	49,942	$0.48M	0.0%	+145.8%	0.080%
5/17/2021	Schonfeld Strategic Advisors LLC	415,692	$3.97M	0.0%	N/A	0.669%
5/17/2021	Royal Bank of Canada	3,148	$30K	0.0%	+326.0%	0.005%
5/17/2021	Nuveen Asset Management LLC	98,905	$0.95M	0.0%	+193.5%	0.159%
5/17/2021	Ikarian Capital LLC	85,837	$0.82M	0.0%	-65.8%	0.138%
5/17/2021	Goldman Sachs Group Inc.	39,249	$0.38M	0.0%	-6.6%	0.063%
5/14/2021	Johnson Investment Counsel Inc.	46,758	$0.45M	0.0%	N/A	0.075%
5/14/2021	Public Employees Retirement System of Ohio	24,903	$0.24M	0.0%	+678.2%	0.040%
5/14/2021	Algert Global LLC	19,410	$0.19M	0.1%	N/A	0.031%
5/13/2021	Knott David M	29,566	$0.28M	0.1%	N/A	0.048%
5/13/2021	Bank of New York Mellon Corp	63,100	$0.60M	0.0%	+113.3%	0.102%
5/12/2021	Northern Trust Corp	165,425	$1.58M	0.0%	+2.0%	0.266%
5/12/2021	Geode Capital Management LLC	402,793	$3.85M	0.0%	+89.2%	0.648%
5/12/2021	Pura Vida Investments LLC	236,311	$2.26M	0.1%	N/A	0.380%
5/12/2021	JPMorgan Chase & Co.	310,862	$2.97M	0.0%	+5,129.0%	0.500%
5/12/2021	UBS Group AG	117,782	$1.13M	0.0%	+9.0%	0.190%
5/11/2021	New York State Common Retirement Fund	20,700	$0.20M	0.0%	+71.1%	0.033%
5/10/2021	Russell Investments Group Ltd.	15,188	$0.14M	0.0%	N/A	0.024%
5/7/2021	BlackRock Inc.	2,826,556	$26.99M	0.0%	+82.5%	4.549%
5/7/2021	American International Group Inc.	19,297	$0.18M	0.0%	+147.2%	0.031%

Data available starting January 2016

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.

Today's Range

Now: $4.34

$4.25

$4.49

50 Day Range

MA: $2.81

$2.00

$4.51

52 Week Range

Now: $4.34

$1.82

$11.10

Volume

558,859 shs

Average Volume

672,159 shs

Market Capitalization

$359.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

Who are the company insiders with the largest holdings of Poseida Therapeutics?: Poseida Therapeutics' top insider shareholders include:
Life Sciences Holdings L Malin (Major Shareholder)
Eric Ostertag (Chairman)
Eric Ostertag (CEO)
Matthew A Spear (Insider)
Kerry D Ingalls (COO)
Life Sciences Holdings L Malin (Director)
Learn More about top insider investors at Poseida Therapeutics.
Who are the major institutional investors of Poseida Therapeutics?: Poseida Therapeutics' top institutional investors include:
FMR LLC — 11.37%
Millennium Management LLC — 1.22%
Laurion Capital Management LP — 0.66%
Silverarc Capital Management LLC — 0.61%
Renaissance Technologies LLC — 0.61%
JPMorgan Chase & Co. — 0.37%
Learn More about top institutional investors of Poseida Therapeutics stock.
Which institutional investors are selling Poseida Therapeutics stock?: Within the previous quarter, PSTX stock was sold by these institutional investors:
State Street Corp
Northern Trust Corp
JPMorgan Chase & Co.
Corton Capital Inc.
Delphia USA Inc.
Forefront Analytics LLC
During the last year, company insiders that have sold Poseida Therapeutics company stock include:
Life Sciences Holdings L Malin (Major Shareholder)
Eric Ostertag (Chairman)
Eric Ostertag (CEO)
Learn More investors selling Poseida Therapeutics stock.
Which institutional investors are buying Poseida Therapeutics stock?: Within the last quarter, PSTX stock was bought by institutional investors including:
Laurion Capital Management LP
Renaissance Technologies LLC
Millennium Management LLC
Silverarc Capital Management LLC
Citadel Advisors LLC
FMR LLC
During the previous year, these company insiders have bought Poseida Therapeutics stock:
Life Sciences Holdings L Malin (Major Shareholder)
Eric Ostertag (Chairman)
Eric Ostertag (CEO)
Matthew A Spear (Insider)
Learn More investors buying Poseida Therapeutics stock.